Navrogen says NAV-005 boosts antibody cancer therapy in CA125-positive tumors

Navrogen published preclinical research July 7, 2026, on NAV-005, a CA125 antagonist designed to restore the activity of monoclonal antibodies and antibody-drug conjugates in CA125-positive cancers. The study, published in BMC Cancer, suggests the program could improve responses to approved antibody-based therapies if it advances into the clinic.

Why it matters: - CA125 can blunt the effect of some antibody cancer drugs by interfering with immune killing and drug delivery inside tumor cells. - Navrogen’s NAV-005 is designed to block that interaction and potentially improve how approved monoclonal antibodies and antibody-drug conjugates work in CA125-positive cancers. - The findings matter because they point to a possible way to overcome one form of humoral immunosuppression that limits treatment response.

What happened: - Navrogen announced new research on NAV-005, a novel immunoglobulin fusion protein antagonist for cancers that overexpress CA125. - The study was published July 7, 2026, in the peer-reviewed journal BMC Cancer. - The paper is available the full report. - Navrogen said NAV-005 is currently in preclinical development.

The details: - The research found that tumor-produced CA125 suppresses monoclonal antibodies and antibody-drug conjugates by binding to the CDR3-framework 4 region of the Ig heavy chain. - That binding blocks complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity through natural killer cells. - CA125 also reduces ADC internalization into targeted tumor cells, which can lower ADC efficacy. - NAV-005 is a high-affinity polypeptide-IgG1 fusion protein that binds both cell-surface and soluble CA125. - By binding CA125, NAV-005 frees mAbs and ADCs from CA125 interference and restores ADC internalization. - Navrogen developed NAV-005 using its proprietary Block Removed Ig Technology platform, or BRITE. - The company said NAV-005 and related therapies are intended to be combined with approved antibody-based treatments in CA125-positive cancers.

Between the lines: - The research positions CA125 as more than a tumor marker; in this setting, it acts as a functional barrier to antibody therapy. - If the platform translates beyond preclinical work, Navrogen could add a companion approach that makes existing antibody drugs work better without replacing them. - Dr. Nicholas Nicolaides, Navrogen’s president and CEO, said the company expects to share more as the program moves toward clinical evaluation.

What's next: - Navrogen said NAV-005 will continue moving toward clinical evaluation. - The company is building a pipeline of therapies aimed at humoral immuno-oncology factors that suppress antibody-based cancer treatment. - Navrogen also markets diagnostic assays intended to identify patients whose tumors produce HIO factors. - More information is available on Navrogen’s website.